Related Experiment Video

Updated: Aug 11, 2026

Single Molecule Analysis of Laser Localized Psoralen Adducts
11:46

Single Molecule Analysis of Laser Localized Psoralen Adducts

Published on: April 20, 2017

Monoclonal antibodies to DNA modified by the carcinogen N-acetoxy-N-2 acetyl aminofluorene

A Le Guern, M Leng, P Kourilsky

    Developments in Biological Standardization
    |January 1, 1984
    PubMed

    BALB/c mice were immunized against acetyl aminofluorene-substituted guanosine (AAF.Guo). Hybridomas were generated from the immune splenocytes fused with the SP2/0.Ag8 cell line. Four monoclonal antibodies (mAb) were selected. Two of them recognize mainly AAF. substituted DNA but also native DNA, while the others (derived from the hybridoma 16) are specific for the modified DNA. Using a solid phase radioimmunoassay, the fine specificity of mAb 16 was examined. The interaction between purified mAb 16 an AAF.DNA is inhibited by either AAF.GMP, AAF.Guo, or AAF.DNA. Moreover this interaction is slightly inhibited by aminofluorene-substituted guanosine (AF.Guo). By control, free AAF, fluorenamine, guanosine, desoxy GMP and native DNA do not compete in the assay. This mAb 16, which specifically recognizes the AAF-nucleotide complex may be a very useful tool to analyze the carcinogenic processes. Such an antibody can also be used for chromosomal localization of genes by AAF-substituted probes.

    More Related Videos

    Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

    Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

    Published on: March 20, 2018

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...